טוען...
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study
BACKGROUND: Biomarkers are urgently needed to dissect the heterogeneity of prostate cancer between patients to improve treatment and accelerate drug development. We analysed blood mRNA expression arrays to identify patients with metastatic castration-resistant prostate cancer with poorer outcome. ME...
שמור ב:
| הוצא לאור ב: | Lancet Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2012
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4878433/ https://ncbi.nlm.nih.gov/pubmed/23059046 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(12)70372-8 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|